ArticleJournal of epidemiology and global health2024
Global Cervical Cancer Incidence by Histological Subtype and Implications for Screening Methods.
Article in Journal of epidemiology and global health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Effectiveness and safety of ICIs for the treatment of advanced CC: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Advanced cervical cancer and its complications: a cross-sectional imaging review.Abdominal radiology (New York) · 2026Review
- Subtype-specific mechanisms of lipid metabolism in gynecological malignancies and novel targeted intervention strategies (Review).Oncology letters · 2026Review
- STK11 Mutations and Deletions Define an Aggressive Molecular Subgroup of Cervical Adenocarcinoma.Cancer medicine · 2026Article
- The Choice Between Definitive Radiotherapy and Surgery for Cervical Cancer With Different Histology in Current Clinical Practice.The Kaohsiung journal of medical sciences · 2026Article
- Time-dependent diffusion MRI for differentiating cervical cancer subtypes: impact of ROI delineation strategies on diagnostic performance.Abdominal radiology (New York) · 2026Article
- Article
- Expression of p16 and p53 proteins in cervical cancer cases in a tertiary centre in Ghana: an immunohistochemical study.BMC cancer · 2026Article
- Therapeutic implications of targeting cancer testis antigen MAGEA1 in cervical cancer.International journal of oncology · 2026Article
- Article
- Article
- Global Comparative Review of Guidelines for Cervical Adenocarcinoma In Situ.Life (Basel, Switzerland) · 2026Review
- Unveiling personalised targets of PD-1 blockade hyperprogression in a cervical adenocarcinoma via longitudinal single-cell and spatial monitoring.NPJ precision oncology · 2026Article
- Single-Cell Transcriptomic Landscape of Cervical Cancer Cell Lines Before and After Chemoradiotherapy.Cells · 2026Article
- Article
- Evaluation of results from KEYNOTE-826 and its impact within the East Asian population with real-world applications.Gynecology and pelvic medicine · 2026Article
- Appraisal the significance of completion hysterectomy after definitive concurrent chemoradiotherapy for patients with locally advanced cervical adenocarcinoma: the ATTRACT study.International journal of surgery (London, England) · 2026Article
- Conclusions Are in Part Inexplicable.Deutsches Arzteblatt international · 2026Article
- In Reply.Deutsches Arzteblatt international · 2026Article
- Challenges in managing cervical cancer in pregnancy: Three case reports.Case reports in women's health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundCervical cancer is a major global health concern, disproportionately affecting women in developing countries. Cervical cancer has two primary subtypes, squamous cell carcinoma (SCC) and adenocarcinoma (AC), each with distinct characteristics and screening effectiveness. In this study, we aimed to estimate the global incidence of cervical cancer according to histological subtype to inform prevention strategies.
methodsUsing data from population-based cancer registries, we computed the rates of SCC, AC, and other specified histology among all cervical cancer cases by country and by 5-year age group. Proportions were subsequently applied to the estimated number of cervical cancer cases from the Global Cancer Observatory 2020. Age-standardized incidence rates were calculated.
resultsSCC accounted for 82.72% of global cervical cancer cases, with AC contributing 12.18%. The highest SCC incidence was in Sub-Saharan Africa (29.79 per 100,000 population). The AC incidence was highest in South-Eastern Asia (3.67 per 100,000 population). Age-specific trends showed SCC peaking at approximately age 55 years and AC plateauing after age 45 years.
conclusionsThis study provided a comprehensive estimate of cervical cancer incidence by histological subtype. SCC remained the dominant subtype globally, whereas the incidence of AC varied across regions. These findings highlighted the need for tailored prevention strategies, especially testing for human papillomavirus to detect AC in high burden areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.